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In 2004, canine inﬂ  uenza virus subtype H3N8 emerged 
in greyhounds in the United States. Subsequent serologic 
evidence indicated virus circulation in dog breeds other than 
greyhounds, but the virus had not been isolated from affect-
ed animals. In 2005, we conducted virologic investigation of 
7 nongreyhound dogs that died from respiratory disease in 
Florida and isolated inﬂ  uenza subtype H3N8 virus. Antigenic 
and genetic analysis of A/canine/Jacksonville/2005 (H3N8) 
and A/canine/Miami/2005 (H3N8) found similarity to earlier 
isolates from greyhounds, which indicates that canine inﬂ  u-
enza viruses are not restricted to greyhounds. The hemag-
glutinin contained 5 conserved amino acid differences that 
distinguish canine from equine lineages. The antigenic ho-
mogeneity of the canine viruses suggests that measurable 
antigenic drift has not yet occurred.  Continued surveillance 
and antigenic analyses should monitor possible emergence 
of antigenic variants of canine inﬂ  uenza virus. 
I
nﬂ  uenza A viruses (family Orthomyxoviridae) are known 
to cause acute respiratory disease in humans, horses, 
pigs, and domestic poultry (1,2). Inﬂ  uenza A virus subtype 
H3N8 has recently emerged as a respiratory pathogen in 
dogs, associated with outbreaks of acute respiratory disease 
in racing greyhounds (3). The disease is caused by a novel 
virus closely related to contemporary equine inﬂ  uenza A 
virus subtype H3N8. These viruses share >96% nucleotide 
sequence identity, which suggests direct transmission of 
the entire virus from horses to dogs without reassortment 
with other strains (3).
Canine inﬂ  uenza virus (CIV) was ﬁ  rst identiﬁ  ed in rac-
ing greyhounds in Florida in January 2004 and was later 
associated with respiratory disease outbreaks in racing 
greyhounds in 9 states from 2004 through 2006 (3,4). Most 
affected greyhounds had clinical signs associated with 
virus infection of the upper respiratory tract—cough for 
10–30 days, nasal discharge, low-grade fever—followed 
by recovery. However, some dogs died peracutely with ex-
tensive hemorrhage in the lungs, mediastinum, and pleural 
cavity. Histologic examination showed tracheitis, bronchi-
tis, bronchiolitis, and suppurative bronchopneumonia asso-
ciated with extensive erosion of epithelial cells and inﬁ  l-
tration with neutrophils. The isolation of 4 closely related 
inﬂ  uenza A subtype H3N8 viruses from dogs that died in 
different geographic locations over a 25-month period, to-
gether with substantial serologic evidence of widespread 
infection among racing greyhounds in 9 states, suggested 
sustained CIV circulation in this population by dog-to-dog 
transmission (3,4).
The ﬁ  rst evidence of CIV infection in dogs other than 
greyhounds came from serologic testing of dogs with acute 
respiratory disease in shelters, boarding kennels, and vet-
erinary clinics in Florida and New York in 2004 and 2005 
(3). Since August 2005, a national syndromic serosurvey 
for canine inﬂ  uenza has been conducted on >5,000 samples 
collected from nongreyhound dogs with compatible clini-
cal signs (Cornell University College of Veterinary Medi-
cine, http://diaglab.vet.cornell.edu/issues/civ-stat.asp).  As 
of April 2008, seropositive dogs have been identiﬁ  ed in 25 
states and the District of Columbia. 
In April and May 2005, an outbreak of respiratory dis-
ease occurred in dogs housed in a shelter facility in north-
eastern Florida (3). The outbreak involved at least 58 dogs, 
ranging in age from 3 months to 9 years, and included pure-
bred dogs as well as mixed breeds; 6 were euthanized. In 
May 2005, a respiratory disease outbreak occurred among 
≈40 pet dogs at a veterinary clinic in southeastern Florida; 
1 died. We performed molecular analyses on 2 inﬂ  uenza 
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Postmortem examinations were performed on the 6 
mixed-breed shelter dogs that died in April and May 2005 
and on the 1 pet Yorkshire terrier that died in the veteri-
nary clinic in May 2005. Tissues were ﬁ  xed in 10% neutral 
buffered formalin and embedded in parafﬁ  n; 5-μm sections 
were stained with hematoxylin and eosin for histopatholog-
ic diagnosis. Unﬁ  xed tissues for virologic and molecular 
analyses were stored at –80oC.
RNA Extraction 
Frozen lung tissues from each dog were thawed and ho-
mogenized in lysis buffer containing β-mercaptoethanol by 
using a disposable tissue grinder (Kendall, Lifeline Medi-
cal Inc., Danbury, CT, USA). Total RNA was extracted by 
using a commercial kit (RNeasy Mini Kit, QIAGEN Inc., 
Valencia, CA, USA) according to manufacturer’s instruc-
tions and eluted in a ﬁ  nal volume of 60 μL of buffer. Total 
RNA was also extracted from lung tissue collected from 
speciﬁ  c-pathogen–free dogs without respiratory disease.
Real-Time Reverse Transcription–PCR
A single-step quantitative real-time reverse transcrip-
tion–PCR (RT-PCR) was performed on total RNA extract-
ed from the canine tissue samples by using the QuantiTect 
Probe RT-PCR Kit containing ROX as a passive reference 
dye (QIAGEN). Brieﬂ  y, 2 primer-probe sets were used for 
detection of inﬂ  uenza A sequences in each sample (Table 
1). One primer-probe set was selective for canine inﬂ  uenza 
subtype H3 gene sequences. The other primer-probe set tar-
geted a highly conserved region of the matrix (M) gene of 
type A inﬂ  uenza virus. The sequence of the M probe con-
tained 3 locked nucleic acids. For each real-time RT-PCR, 
5 μL of total RNA was added to a reaction mixture contain-
ing 12.5 μL of 2× QuantiTect Probe RT-PCR Master Mix, 
0.25 μL of QuantiTech RT Mix (both QIAGEN), forward 
and reverse primers (0.4 μmol/L ﬁ  nal concentration for 
each), probe (0.1 μmol/L ﬁ  nal concentration), and RNase-
free water in a ﬁ  nal volume of 25 μL. Real-time PCR for 
eukaryotic 18S rRNA was performed by using commer-
cially available assay reagents (VIC/TAMRA; TaqMan, 
Applied Biosystems, Foster City, CA, USA), according to 
manufacturer’s instructions for detection of endogenous 
18S rRNA, as an internal control for RNA extraction from 
the tissues.
Quantitative one-step real-time RT-PCR was per-
formed on the reaction mixtures in an Mx3000P QPCR 
System (Stratagene, La Jolla, CA, USA). Cycling condi-
tions were a reverse transcription step at 50°C for 30 min, 
an initial denaturation step at 95°C for 15 min to activate 
the HotStarTaq DNA Polymerase (QIAGEN), and ampli-
ﬁ  cation for 40 cycles. Each ampliﬁ  cation cycle included 
denaturation at 94°C for 15 s, followed by annealing/exten-
sion at 60°C for 1 min. The FAM (emission wavelength 
516 nm) and VIC (emission wavelength 555 nm) ﬂ  uores-
cent signals were recorded at the end of each cycle. The 
threshold cycle (Ct) was determined by setting the thresh-
old ﬂ  uorescence at 1,000 for each individual experiment. 
The Mx3000P version 2.0 software program (Stratagene) 
was used for data acquisition and analysis. The results were 
normalized by calculating H3 Ct or M Ct to 18S rRNA Ct 
ratios for each sample. Samples were considered positive 
for inﬂ  uenza A virus when the normalized H3 or M Ct ratio 
was 3 U smaller than the normalized Ct ratio for lung tis-
sues from dogs without respiratory disease. The positive 
control was ampliﬁ  ed RNA that had been extracted from 
A/canine/Florida/242/2003 (H3N8) virus grown in MDCK 
cells (3).
Virus Isolation
Inoculation of Cell Culture 
Frozen lung tissues from each of the 7 dogs were 
thawed and homogenized in 10 volumes of Dulbecco mod-
iﬁ  ed Eagle medium (DMEM) supplemented with 0.5% bo-
vine serum albumin and gentamicin and ciproﬂ  oxacin. Sol-
id debris was removed by centrifugation, and supernatants 
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Table 1. Primers and probes for identification of canine influenza virus (H3N8) in tissues by quantitative real-time reverse 
transcription–PCR* 
Primer Target  Sequence    Application 
Ca-H3-F387  H3 (nt 387–406)  5ƍ-tatgcatcgctccgatccat-3ƍ  Forward primer for H3 
Ca-H3-R487  H3 (nt 487–467)  5ƍ-gctccacttcttccgttttga-3ƍ  Reverse primer for H3 
Ca-H3-P430  H3 (nt 430–459)  FAM-aattcacagcagagggattcacatggacag-BHQ1  TaqMan probe 
FluA-M-F151  M (nt 151–174)  5ƍ-catggartggctaaagacaagacc-3ƍ  Forward primer for M 
FluA-M-R276  M (nt 276–253)  5ƍ-agggcattttggacaaakcgtcta-3ƍ  Reverse primer for M 
FluA-M-P218  M (nt 218–235)  FAM-acgcTcaccgTgcccAgt-BHQ1  TaqMan probe 
*Conserved regions of the matrix (M) and hemagglutinin 3 (H3) genes of canine influenza virus were selected. The underlined r represents a mixture of a 
and g nucleotides at this position in the oligonucleotide; the underlined k represents mixtures of g or t; uppercase letters in the sequence for the M probe 
represent locked nucleic acids. RESEARCH
were inoculated onto MDCK cells cultured in DMEM sup-
plemented with 1 μg/mL TPCK (L-1-tosylamido-2-phenyl-
ethyl chloromethyl ketone)–treated trypsin (Sigma-Aldrich 
Corp., St. Louis, MO, USA), 0.35% bovine serum albumin, 
and antimicrobial drugs. Cells were grown in 25-cm2 ﬂ  asks 
at 37°C in a humidiﬁ  ed atmosphere containing 5% CO2. 
The cultures were observed daily for morphologic changes 
and harvested 3 days after inoculation. The harvested cul-
tures were clariﬁ  ed by centrifugation, and the supernatants 
were inoculated onto fresh MDCK cells as described for 
the initial inoculation; up to 3 additional passages were per-
formed for samples that did not show evidence of inﬂ  uenza 
virus by hemagglutination or RT-PCR. Hemagglutination 
activity in the clariﬁ  ed supernatants was determined by us-
ing 0.5% turkey red blood cells as described (5,6). RT-PCR 
was performed as described below.
Inoculation of Embryonated Chicken Eggs 
Frozen lung tissues were homogenized as described 
above for inoculation of MDCK cells by using phosphate-
buffered saline instead of DMEM, and a volume of 0.2 mL 
was inoculated into the allantoic sac of 10-day old embryo-
nated chicken eggs. After 48 h of incubation at 35°C, the 
eggs were chilled at 4°C overnight before the allantoic ﬂ  uid 
was harvested. Hemagglutination activity in the clariﬁ  ed 
allantoic ﬂ  uid supernatants was determined by using 0.5% 
turkey red blood cells as described (5,6). RT-PCR was per-
formed as described below. Harvested allantoic ﬂ  uid sam-
ples lacking evidence of inﬂ  uenza virus were reinoculated 
up to 2 more times in embryonated eggs and evaluated as 
described.
RT-PCR, Nucleotide Sequencing, and Phylogenetic 
Analyses
Virus RNA was extracted from MDCK culture super-
natant or allantoic ﬂ  uid by using the QIAamp Viral RNA 
Mini Kit (QIAGEN) according to manufacturer’s instruc-
tions. The virus RNA was reverse transcribed to cDNA 
by using the QIAGEN OneStep RT-PCR Kit according to 
manufacturer’s instructions. PCR ampliﬁ  cation of the cod-
ing region of the 8 inﬂ  uenza virus genes in the cDNA was 
performed as described (7) by using universal gene-speciﬁ  c 
primer sets (3). The resulting DNA amplicons were used 
as templates for automated sequencing in the ABI PRISM 
3100 automated DNA sequencer by using cycle sequencing 
dye terminator chemistry (Applied Biosystems). Nucleotide 
sequences were analyzed by using the Lasergene 6 Pack-
age (DNASTAR, Inc., Madison, WI, USA). The PHYLIP 
Version 3.5 software program was used to estimate phy-
logenies and calculate bootstrap values from the nucle-
otide sequences (8). Phylogenetic trees were compared 
with those generated by neighbor-joining analysis with the 
Tamura-Nei model implemented in the MEGA3 program 
(9) and conﬁ  rmed by the PAUP 4.0 Beta program (Sinauer 
Associates, Inc., Sunderland, MA, USA). The complete ge-
nome sequences from the 2 new reported CIV isolates (A/
canine/Miami/2005 and A/canine/Jacksonville/2005) were 
deposited in GenBank under accession nos. EU402407–
EU402408 and EU534193–EU534204.
Hemagglutination Inhibition Assay
Convalescent-phase immune serum samples were 
obtained from horses and dogs naturally infected with in-
ﬂ  uenza A virus (H3N8) in 2005. Antiserum from ferrets 
infected with A/canine/Florida/43/2004 (H3N8) was pre-
pared as described (3). All serum samples were incubated 
with receptor-destroying enzyme (DENKA SEIKEN Co., 
Ltd., Tokyo, Japan) (1 part serum: 3 parts receptor-destroy-
ing enzyme) for 16 h at 37°C before heat inactivation for 30 
min at 56°C. Inﬂ  uenza A/canine/Jacksonville/2005 virus 
(H3N8) was grown in MDCK cells for 72 h at 37°C in 5% 
CO2. Virus culture supernatants were harvested, clariﬁ  ed 
by centrifugation, and stored at –80°C. All other canine 
and equine viruses used in the hemagglutination inhibition 
(HI) assay were grown in 10-day old embryonated chicken 
eggs from which allantoic ﬂ  uid was collected after 72 h and 
stored at –80°C. The HI assay was performed as described 
(6). On the basis of assay results from serum of uninfected 
speciﬁ  c-pathogen–free dogs with HI titers <4, HI titers >32 
were considered as evidence of previous exposure to CIV.
Results
Clinical Findings 
Among the 58 affected shelter dogs, the most common 
clinical signs were low-grade fever, purulent nasal dis-
charge, and cough for 10–21 days. Paired acute- and con-
valescent-phase serum samples were collected from 5 dogs 
and tested for CIV-speciﬁ  c antibodies by using the HI assay. 
All the dogs seroconverted to A/canine/Florida/43/2004 
(H3N8) and had an increase in the geometric mean anti-
body titer (GMT) from 37 in the acute phase to 626 in the 
convalescent phase. Single serum samples were collected 
from another 18 dogs that had had clinical disease for at 
least 7 days, and 17 (94%) were seropositive for A/canine/
Florida/43/2004 (H3N8); HI antibody titers ranged from 32 
to 2,048 and GMT was 533. Pneumonia developed in at 
least 10 dogs, of which 6 were euthanized and submitted 
for postmortem examination. These 6 mixed-breed dogs 
were 3 males and 3 females ranging in age from 4 months 
to 3 years. The duration of clinical signs at the time of eu-
thanasia was 2–10 days.
Among the ≈40 affected pet dogs at the veterinary 
clinic, the most common clinical signs were low-grade fe-
ver, purulent nasal discharge, and cough for 10–30 days. 
Paired acute- and convalescent-phase serum samples were 
904  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 6, June 2008 Inﬂ  uenza A Virus (H3N8), Dogs 
collected from 19 dogs and tested for CIV-speciﬁ  c anti-
bodies by using the HI assay. Of these, 11 (58%) dogs 
seroconverted to A/canine/Florida/43/2004 (H3N8), and 
the GMT increased from 9 in the acute phase to 329 in the 
convalescent phase. Single serum samples were collected 
from another 9 dogs that had had clinical disease for at 
least 7 days, and 6 (67%) were seropositive for A/canine/
Florida/43/2004 (H3N8); HI antibody titers ranged from 64 
to 512 and GMT was 228. Pneumonia developed in 3 dogs; 
1, a 9-year-old male Yorkshire terrier, died 3 days after 
onset of clinical signs and was submitted for postmortem 
examination.
Postmortem examinations showed that all 7 dogs had 
tracheitis and bronchitis with inﬂ  ammatory changes that in-
volved submucosal glands. Tracheitis and bronchitis were 
characterized by surface and glandular epithelial necrosis 
and hyperplasia with inﬁ  ltration by lymphocytes, neutro-
phils, and macrophages. Suppurative bronchopneumonia 
was found in 2 of the shelter dogs and the pet dog; histo-
logically identiﬁ  ed bacteria in the lesions indicated a bac-
terial contribution to the pneumonic lesions. None of the 
dogs had intrathoracic or pulmonary hemorrhage.
Laboratory Diagnosis 
Lung tissues from the 7 dogs were analyzed by quan-
titative real-time RT-PCR assays that detect the M gene 
of inﬂ  uenza A and the H3 gene of CIV. The M and H3 
genes were ampliﬁ  ed from the lungs of all 7 dogs, which 
conﬁ  rmed the presence of CIV (Table 2). Lung tissue from 
the speciﬁ  c-pathogen–free dogs did not show evidence of 
ampliﬁ   cation of inﬂ   uenza virus genes. MDCK cultures 
were inoculated with these lung homogenates to identify 
viable inﬂ  uenza virus. Pathologic cell damage was noted 
in the MDCK cell monolayer on the third passage of the 
lung homogenate from 1 of the shelter dogs that died after 
3 days of pneumonia. Inﬂ  uenza A virus (later identiﬁ  ed as 
subtype H3N8) was recovered from the supernatant, and 
the isolate was named A/canine/Jacksonville/2005. After 
2 passages in embryonated chicken eggs, inﬂ  uenza A vi-
rus (later identiﬁ  ed as subtype H3N8) was recovered from 
the lung homogenate of the pet dog that also died of pneu-
monia 3 days after onset. This virus was named A/canine/
Miami/2005. These isolates provided virologic evidence of 
CIV infection in nongreyhound dogs.
Genetic Analyses of the Canine Inﬂ  uenza A (H3N8) 
Isolates
Sequence analyses of A/canine/Jacksonville/2005 
and A/canine/Miami/2005 showed that their H3 gene nu-
cleotide sequences were 98% identical to those of the A/
canine/Florida/242/2003, A/canine/Florida/43/2004, A/ca-
nine/Texas/2004, and A/canine/Iowa/2005 isolates recov-
ered from the lungs of racing greyhounds that died of pneu-
monia during inﬂ  uenza outbreaks in 2004 and 2005 (3,4). 
Phylogenetic comparisons of the H3 genes showed that 
the A/canine/Jacksonville/2005 and A/canine/Miami/2005 
viruses from nongreyhound dogs clustered with the grey-
hound isolates and contemporary equine isolates, forming a 
distinct group from the older equine viruses isolated in the 
early 1990s (Figure, panel A). Furthermore, the A/canine/
Jacksonville/2005, A/canine/Miami/2005, and A/canine/
Iowa/2005 isolates were more closely related to A/canine/
Texas/2004 than to either A/canine/Florida/43/2004 or A/
canine/Florida/242/2003. The H3 genes from the 2005 iso-
lates formed a subgroup that appeared to branch off from 
the earlier 2003 and 2004 canine viruses with nucleotide 
differences at 10 sites. Most nucleotide changes are silent, 
as can be appreciated by the shorter branch lengths in the 
phylogenetic tree constructed from deduced amino acid se-
quence data (Figure, panel B).
Amino Acid Sequence of the CIV H3 Hemagglutinin
To identify changes with possible functional signiﬁ  -
cance with regard to antigenicity or receptor binding, we 
compared the deduced amino acid sequences of the H3 
hemagglutinins from the 6 available CIV isolates. All 6 
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Table 2. Quantitative real-time reverse transcription–PCR and virus isolation from tissue specimens* 
Real-time reverse transcription–PCR 
Dog Location
Duration of 
clinical disease, d  18S rRNA (Ct)  M (Ct)  M:rRNA H3 (Ct)  H3:rRNA Virus isolation 
1079 Shelter 2 26.18 29.81 1.14 28.84 1.10 NVD
1078 Shelter 3 26.82 30.37 1.13 29.71 1.11 MDCK cells 
3rd passage
1080 Shelter 6   24.17 38.87 1.61 38.23 1.58 NVD
319 Shelter 6   24.94 33.87 1.36 32.23 1.29 NVD
318 Shelter 9   23.54 33.89 1.44 32.97 1.40 NVD
320 Shelter 10   23.91 39.44 1.65 37.09 1.55 NVD
374 Veterinary clinic  3 22.89 24.05 1.05 22.65 0.99 Egg
2nd passage 
A/canine/Florida/242/2003 29.37 28.15 0.96 27.36 0.93 NA
Normal dog lung  20.78 >40 >1.92 >40 >1.92 NA
*Ct, cycle threshold; NVD, no virus detected; NA, not applicable; M:rRNA and H3:rRNA ratios were calculated by dividing the matrix (M) or hemagglutinin 
3 (H3) Ct by the 18S rRNA Ct. RESEARCH
canine isolates had 5 conserved amino acid substitutions 
that differentiated them from contemporary equine inﬂ  uen-
za viruses (Table 3). These conserved substitutions (N54K, 
N83S, W222L, I328T, and N483T) can be considered as a 
signature of the circulating CIV H3 hemagglutinin. Phylo-
genetic comparisons of the mature H3 protein showed that 
the A/canine/Jacksonville/2005, A/canine/Miami/2005, and 
A/canine/Iowa/2005 viruses formed a subgroup with the A/
canine/Texas/2004 isolate (Figure, panel B). Three amino 
acid changes (L118V, K261N, and G479E) differentiated 
this subgroup from the earlier A/canine/Florida/43/2004 
and A/canine/Florida/242/2003 isolates (Table 3). Final-
ly, A/canine/Jacksonville/2005 differed from A/canine/
Miami/2005 at a single amino acid, S107P.
Antigenic Analyses of the Canine 
Inﬂ  uenza A (H3N8) Isolates
HI tests were performed by using an antigen panel of 
previously circulating and contemporary equine inﬂ  uenza 
viruses and the available CIVs as well as convalescent-
phase immune serum from horses and dogs naturally infect-
ed with inﬂ  uenza virus (H3N8) in 2005 (Table 4). An anti-
serum from ferrets infected with A/canine/Florida/43/2004 
was also included in the analyses. HI antibody titers in 
equine serum were 2-fold to 16-fold higher with contem-
porary equine viruses (1999–2003) than with older isolates 
(1963–1992). The heterologous titers of equine serum to 
canine viruses were generally similar to the homologous 
values for the contemporary equine viruses. The canine se-
rum failed to substantially inhibit hemagglutination by the 
older equine inﬂ  uenza viruses (1963–1992), but the anti-
body titers to contemporary equine isolates (1999–2003) 
and the canine isolates were comparable. Similar results 
were observed for serum from ferrets infected with CIV. 
These patterns of inhibition demonstrated the antigenic 
similarity between the CIVs and contemporary equine in-
ﬂ  uenza viruses and were consistent with the phylogenetic 
analyses. The antibody titers to the A/canine/Miami/2005 
isolate in equine, canine, and ferret serum were similar to 
those for the 2003 and 2004 canine isolates, which indi-
cates that the amino acid substitutions in the isolates did not 
result in measurable antigenic drift. The antibody titers to 
the A/canine/Jacksonville/2005 isolate were, in general, 2- 
to 4-fold lower than those to A/canine/Florida/43/2004 and 
other canine viruses, which suggests a potential antigenic 
difference.
Discussion
The genetic and phylogenetic analyses of inﬂ  uenza A 
subtype H3N8 viruses recovered from racing greyhounds 
affected by respiratory disease outbreaks and fatal pneu-
monia in 2003 and 2004 have been described (3). These 
greyhound inﬂ   uenza viruses were most homologous to 
contemporary equine inﬂ  uenza A subtype H3N8 viruses 
isolated from horses in 2002 and 2003. Although serologic 
evidence of inﬂ  uenza virus infection in nongreyhound dogs 
was reported (3), whether these infections were caused by 
the same virus that infected the greyhound dogs is not 
clear. The inﬂ  uenza subtype H3N8 viruses that we describe 
in this report came from nongreyhound dogs involved in 
fatal canine inﬂ  uenza outbreaks independent of any known 
outbreaks in greyhounds.
Because viral hemagglutinin is a critical determinant 
of the host speciﬁ  city of inﬂ  uenza virus (10), we compared 
the nucleic acid and deduced amino acid sequences for the 
canine and equine H3 to identify residues that may be as-
sociated with efﬁ  cient replication in different species or 
dog breeds. The 5 conserved amino acid substitutions in all 
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Figure. Phylogenetic relationships among the hemagglutinin 3 (H3) 
genes. A) Nucleotide tree of the canine inﬂ  uenza virus H3 genes 
with contemporary and older equine H3 genes. B) Amino acid tree 
of the canine inﬂ   uenza virus H3 protein with contemporary and 
older equine H3 proteins. Bootstrap analysis values >80% are 
shown. Scale bar indicates nucleotide or amino acid substitutions 
per site. Inﬂ  uenza A Virus (H3N8), Dogs 
the canine viruses differentiated them from contemporary 
equine viruses. The substitution of lysine for asparagine at 
position 54 maintains the positive charge of the residue and 
is of unknown functional signiﬁ  cance. Position 83 located 
within antigenic site E of human H3 has been implicated 
in antigenic drift (11). The substitution of serine for as-
paragine at position 83 in canine H3 maintains the polar 
nature of the residue, but the functional signiﬁ  cance in the 
evolution of canine inﬂ  uenza is not immediately apparent. 
The substitution of leucine for tryptophane at position 222 
represents a nonconservative change adjacent to the sialic 
acid–binding pocket, which suggests a potential modulator 
function in adaptation of equine inﬂ  uenza virus to canine 
sialic acid receptors. This leucine substitution has also been 
reported in avian inﬂ  uenza subtype H4 infection of pigs 
(12) and subtype H9 infection of humans (13). The strictly 
conserved isoleucine at position 328 near the cleavage site 
of the equine H3 hemagglutinin has been replaced by threo-
nine in all the canine isolates, which suggests the potential 
importance of threonine for recognition of the hemagglu-
tinin cleavage site by canine proteases. The replacement 
of asparagine with threonine at position 483 results in the 
loss of a glycosylation site in the hemagglutinin 2 (HA2) 
subunit. This glycosylation site is conserved in all other he-
magglutinin subtypes (14).
The phylogenetic tree of the canine and equine inﬂ  u-
enza H3 genes shows that the canine and equine lineages 
have diverged considerably. The hemagglutinin sequences 
from the 2004 and 2005 equine inﬂ  uenza isolates belong 
to the Florida sublineage and do not have the mutations 
found in the canine strains. The H3 genes from the 2 Flori-
da 2005 canine isolates formed a clade with high bootstrap 
support that included A/canine/Texas/2004 and A/canine/
Iowa/2005. Three amino acid substitutions in H3—L118V, 
K261N, and G479E—differentiated this group from the 
earlier isolates. Positions 118 and 261 are in the hemag-
glutinin 1 (HA1) subunit of canine H3; position 479 is in 
the HA2 subunit. The HA1 subunit of human H3 contains 
the antibody-binding sites where amino acid substitutions 
occur at high frequency, presumably the result of escape 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 6, June 2008  907 
Table 3. Amino acid differences among the hemagglutinin proteins of canine and contemporary equine influenza viruses*  
Amino acid positions in mature HA 
Virus 7† 29 54 78 79 83 92 107 118 159 218 222 261 328 479 483 492 541
A/equine/Kentucky/5/2002 G I N V F N S S L N G W K I G N R K
A/equine/Massachusetts/213/2003  ... A .....S ........
A/equine/Ohio/1/2003  ... A .....S ........
A/equine/Bari/2005 D .................
A/canine/Florida/242/2003 D . K A . S...S . L.T.T..
A/canine/Florida/43/2004 . M K A . S N ..S . L.T.T.R
A/canine/Texas/1/2004  . M K A . S..V S . L N T E T..
A/canine/Iowa/2005  . M K A L S..V S E L N T E T..
A/canine/Miami/2005 . M K A . S..V S . L N T E T K .
A/canine/Jacksonville/2005  . M K A . S.P V S . L N T E T K .
*Dots represent the same amino acids as in A/equine/Kentucky/5/2002 hemagglutinin (HA). Conserved residues in the canine HA  that differentiate them 
from the equine HA are in boldface within blue-shaded boxes. Residues that differentiate the A/canine/Texas/2004 clade from A/canine/Florida/242/2003 
and A/canine/Florida/43/2004 are in boldface within gray-shaded boxes.  
†Only variable positions are shown; numbering is for mature HAO. 
Table 4. Hemagglutination inhibition antibody titers to older and contemporary equine viruses and canine influenza viruses*  
Serum sample no. 
Equine† Canine‡ Ferret§ 
Virus 65694 73147 84376 13 25 27 A/canine/Florida/43/2004
A/equine/Miami/63 40 40 160 <10 <10 10 16
A/equine/Kentucky/86 40 40 160 10 40 40 32
A/equine/Kentucky/92 40 20 80 <10 <10 10 32
A/equine/NewYork/99 320 40 320 40 160 40 128
A/equine/Kentucky/05/2002 320 40 320 40 160 160 256
A/equine/Massachussetts/213/2003 640 80 320 40 160 160 512
A/equine/Ohio/01/2003 640 80 320 80 320 160 512
A/canine/Florida/242/2003 160 40 320 40 160 160 512
A/canine/Texas/2004 160 40 320 40 160 160 512
A/canine/Florida/43/2004 160 40 320 40 160 80 512
A/canine/Miami/2005 320 40 320 40 160 80 256
A/canine/Jacksonville/2005  40 10 80 20 40 40 128
*The antibody titer is the reciprocal of the highest serum dilution that inhibited hemagglutination by the virus. 
†Serum from horses infected with equine influenza virus in 2005.  
‡Serum from dogs infected with canine influenza virus in 2005. 
§Serum from ferrets infected with A/canine/Florida/43/2004 (H3N8). RESEARCH
from humoral immune responses (11,15,16). Although no 
evidence supports high variability at positions 118 and 261, 
neighboring positions 121 (antigenic site D) and 262 (anti-
genic site E) are sites of frequent positive selection in hu-
man H3 genes (11). The 2005 isolates from nongreyhound 
dogs differed from each other by substitution of proline 
for serine at position 107 in the HA1 subunit of A/canine/
Jacksonville/2005. Serine is conserved at position 107 in 
all other equine and canine isolates except for A/equine/
Jilin/1/89, which has a threonine substitution (17). A/ca-
nine/Jacksonville/2005 has potentially signiﬁ  cant antigenic 
variation from the other canine isolates, which may be 
partially related to the proline substitution at position 107. 
However, no serologic evidence indicates that residue 107 
modulates the antigenicity of human, porcine, or equine H3 
hemagglutinins.
The HI results showed antigenic similarity between 
the canine and contemporary equine inﬂ  uenza viruses and 
were in agreement with the phylogenetic clustering of ca-
nine hemagglutinin sequences near the equine counterparts. 
The amino acid and antigenic differences between canine 
and equine hemagglutinin illustrate the ongoing process of 
divergent evolution of the canine viruses from the ancestral 
equine viruses. These differences also support the hypoth-
esis that CIV is a separate virus lineage, which is efﬁ  ciently 
maintained in the dog population by horizontal dog-to-dog 
transmission.
With the introduction and sustained transmission of 
inﬂ   uenza virus (H3N8) in dogs, the H3 hemagglutinin 
became the most broadly distributed subtype in mamma-
lian species, including humans, swine, horses, and dogs. 
Continued virologic and serologic surveillance will be im-
portant for monitoring the evolution of CIV and its health 
effects in dogs as well as the possible transmission to other 
species, including humans.
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